213 related articles for article (PubMed ID: 32910830)
1. Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study.
Yan H; Valdes AM; Vijay A; Wang S; Liang L; Yang S; Wang H; Tan X; Du J; Jin S; Huang K; Jiang F; Zhang S; Zheng N; Hu Y; Cai T; Aithal GP
Clin Pharmacol Ther; 2020 Dec; 108(6):1185-1194. PubMed ID: 32910830
[TBL] [Abstract][Full Text] [Related]
2. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D
J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
[TBL] [Abstract][Full Text] [Related]
4. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain.
Vila-Corcoles A; Satue-Gracia E; Ochoa-Gondar O; Torrente-Fraga C; Gomez-Bertomeu F; Vila-Rovira A; Hospital-Guardiola I; de Diego-Cabanes C; Bejarano-Romero F; Rovira-Veciana D; Basora-Gallisa J
J Clin Hypertens (Greenwich); 2020 Aug; 22(8):1379-1388. PubMed ID: 32710674
[TBL] [Abstract][Full Text] [Related]
5. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Ren L; Yu S; Xu W; Overton JL; Chiamvimonvat N; Thai PN
J Cardiol; 2021 May; 77(5):482-491. PubMed ID: 33168337
[TBL] [Abstract][Full Text] [Related]
6. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W
PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.
Sandhu AT; Kohsaka S; Lin S; Woo CY; Goldstein MK; Heidenreich PA
Am Heart J; 2021 Oct; 240():46-57. PubMed ID: 34126079
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
An J; Wei R; Zhou H; Luong TQ; Gould MK; Mefford MT; Harrison TN; Creekmur B; Lee MS; Sim JJ; Brettler JW; Martin JP; Ong-Su AL; Reynolds K
J Am Heart Assoc; 2021 Feb; 10(3):e019669. PubMed ID: 33307964
[TBL] [Abstract][Full Text] [Related]
9. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service.
Kim J; Kim DW; Kim KI; Kim HB; Kim JH; Lee YG; Byeon KH; Cheong HK;
J Korean Med Sci; 2020 Jun; 35(25):e232. PubMed ID: 32597045
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive medications and COVID-19 diagnosis and mortality: Population-based case-control analysis in the United Kingdom.
Rezel-Potts E; Douiri A; Chowienczyk PJ; Gulliford MC
Br J Clin Pharmacol; 2021 Dec; 87(12):4598-4607. PubMed ID: 33908074
[TBL] [Abstract][Full Text] [Related]
11. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.
Bezabih YM; Bezabih A; Alamneh E; Peterson GM; Bezabhe W
BMC Infect Dis; 2021 Jun; 21(1):527. PubMed ID: 34090358
[TBL] [Abstract][Full Text] [Related]
12. Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19.
Loader J; Lampa E; Gustafsson S; Cars T; Sundström J
J Am Heart Assoc; 2021 Aug; 10(15):e021154. PubMed ID: 34320843
[TBL] [Abstract][Full Text] [Related]
13. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
[TBL] [Abstract][Full Text] [Related]
14. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
[TBL] [Abstract][Full Text] [Related]
15. Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19.
Ramos-Rincón JM; Pérez-Belmonte LM; Carrasco-Sánchez FJ; Jansen-Chaparro S; De-Sousa-Baena M; Bueno-Fonseca J; Pérez-Aguilar M; Arévalo-Cañas C; Bacete Cebrian M; Méndez-Bailón M; Fiteni Mera I; González García A; Navarro Romero F; Tuñón de Almeida C; Muñiz Nicolás G; González Noya A; Hernández Milian A; García García GM; Alcalá Pedrajas JN; Herrero García V; Corral-Gudino L; Comas Casanova P; Meijide Míguez H; Casas-Rojo JM; Gómez-Huelgas R;
J Gerontol A Biol Sci Med Sci; 2021 Jul; 76(8):e102-e109. PubMed ID: 33945610
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care.
Haroon S; Subramanian A; Cooper J; Anand A; Gokhale K; Byne N; Dhalla S; Acosta-Mena D; Taverner T; Okoth K; Wang J; Chandan JS; Sainsbury C; Zemedikun DT; Thomas GN; Parekh D; Marshall T; Sapey E; Adderley NJ; Nirantharakumar K
BMC Infect Dis; 2021 Mar; 21(1):262. PubMed ID: 33722197
[TBL] [Abstract][Full Text] [Related]
17. Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.
Ma Z; Wang MP; Liu L; Yu S; Wu TR; Zhao L; Zhang YP; Liang HF; Yang XC
Aging (Albany NY); 2021 Apr; 13(8):10853-10865. PubMed ID: 33886504
[TBL] [Abstract][Full Text] [Related]
18. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
[TBL] [Abstract][Full Text] [Related]
19. Adherence to Oral Medications for Hypertension and Diabetes in Veterans with Comorbid Airflow Limitation.
Melzer AC; Uman J; Au DH
Ann Am Thorac Soc; 2015 Jun; 12(6):831-7. PubMed ID: 25849224
[TBL] [Abstract][Full Text] [Related]
20. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.
Singh AK; Gupta R; Misra A
Diabetes Metab Syndr; 2020; 14(4):283-287. PubMed ID: 32283499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
